{"id":"W2570401170","doi":"10.1007/s40257-016-0246-9","title":"Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)","year":2017,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Etanercept; Plaque psoriasis; Randomized controlled trial; Psoriasis; Pharmacotherapy; Clinical trial; Internal medicine; Dermatology; Psoriatic arthritis; Secukinumab; Tumor necrosis factor alpha","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01390561,0.000382115,0.008181487,0.0006261823,0.0001565174,0.00004568936,0.000549446,0.0004246157,0.00008213489],"category_scores_gemma":[0.02079785,0.0002908849,0.0008701276,0.0002504001,0.0009175844,0.000210844,0.0002204459,0.0008246789,0.0000158323],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003495458,"about_ca_system_score_gemma":0.0003308532,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001307718,"about_ca_topic_score_gemma":0.0007797664,"domain_scores_codex":[0.9807137,0.01168067,0.006425751,0.0006135544,0.0001119608,0.0004543504],"domain_scores_gemma":[0.9642026,0.03085714,0.003965582,0.0005701318,0.0001511524,0.0002534272],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5335701,0.0006773206,0.04857624,0.0000072811,0.00232037,0.0002867378,0.001211819,0.00008561164,0.0008892723,0.00004663362,0.00008735265,0.4122413],"study_design_scores_gemma":[0.844457,0.002274402,0.1454266,0.0004024945,0.002378906,0.000536521,0.001329562,0.0004287088,0.0008336839,0.0006831823,0.0006644493,0.000584588],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921649,0.0007693544,0.002266195,0.003284116,0.0007428876,0.0006551763,0.00005158806,0.000006725184,0.00005907688],"genre_scores_gemma":[0.9953949,0.002229203,0.00160907,0.0005639874,0.0001288611,0.00001593025,0.00001463182,0.00002287323,0.00002056677],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4116567,"threshold_uncertainty_score":0.9999543,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06534057836563588,"score_gpt":0.4286594761625303,"score_spread":0.3633188977968944,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}